GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (OTCPK:GLAXF) » Definitions » Cyclically Adjusted Revenue per Share

GSK (GLAXF) Cyclically Adjusted Revenue per Share : $10.61 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is GSK Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Dec. 2023 was $2.474. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $10.61 for the trailing ten years ended in Dec. 2023.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 1.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 8.90% per year. The lowest was 0.60% per year. And the median was 5.05% per year.

As of today (2024-04-29), GSK's current stock price is $21.30. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $10.61. GSK's Cyclically Adjusted PS Ratio of today is 2.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.72. The lowest was 1.57. And the median was 2.10.


GSK Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.15 9.92 10.50 10.00 10.61

GSK Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.00 10.41 10.79 10.12 10.61

Competitive Comparison of GSK's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.



GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.474/130.0000*130.0000
=2.474

Current CPI (Dec. 2023) = 130.0000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2.395 99.300 3.135
201406 2.413 99.800 3.143
201409 2.363 100.000 3.072
201412 2.515 99.900 3.273
201503 2.161 99.600 2.821
201506 2.352 100.100 3.055
201509 2.409 100.200 3.125
201512 2.384 100.400 3.087
201603 2.268 100.400 2.937
201606 2.387 101.000 3.072
201609 2.527 101.500 3.237
201612 2.388 102.200 3.038
201703 2.317 102.700 2.933
201706 2.397 103.500 3.011
201709 2.649 104.300 3.302
201712 2.575 105.000 3.188
201803 2.550 105.100 3.154
201806 2.449 105.900 3.006
201809 2.659 106.600 3.243
201812 2.601 107.100 3.157
201903 2.535 107.000 3.080
201906 2.479 107.900 2.987
201909 2.900 108.400 3.478
201912 2.881 108.500 3.452
202003 2.807 108.600 3.360
202006 2.375 108.800 2.838
202009 2.778 109.200 3.307
202012 -0.335 109.400 -0.398
202103 2.553 109.700 3.025
202106 2.028 111.400 2.367
202109 2.245 112.400 2.597
202112 2.317 114.700 2.626
202203 2.330 116.500 2.600
202206 1.680 120.500 1.812
202209 2.169 122.300 2.306
202212 2.197 125.300 2.279
202303 2.065 126.800 2.117
202306 1.771 129.400 1.779
202309 2.452 130.100 2.450
202312 2.474 130.000 2.474

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GSK  (OTCPK:GLAXF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=21.30/10.61
=2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.72. The lowest was 1.57. And the median was 2.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (GLAXF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (OTCPK:GLAXF) » Definitions » Cyclically Adjusted Revenue per Share
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.